
|Videos|October 11, 2011
Dr. Goy on Novel Therapies at the JTCC Conference
Dr. Andre Goy from John Theurer Cancer Center on Integrating Novel Therapies Into the JTCC Conference
Advertisement
Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses how novel treatment options have revolutionized treatment for patients with non-small cell lung cancer, a disease that used to be considered “beyond surgery.”
Novel therapies, new characterizations of tumors, and a more personalized approach to treating these tumors will be discussed at the upcoming
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5




































